Skip to main content

Table 3 Toxicity and supportive care - supportive treatment.

From: A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study

  CP
N= 90
CLD
N = 87
Antibiotics 9 (10) 14 (16)
Granulocyte colony-stimulating factor 41 (46) 45 (52)
RBC transfusion † 3 (3) 12 (14)
Platelet transfusion 0 (0) 3 (3)
Hospitalization 11 (12) 13 (15)
  1. † Red blood cell (RBC) transfusion rate is higher among patients treated in group B (3% in group A versus 14% in group B, P = 0.015)